NL-OMON41271已完成4 期
A phase IV, randomized, double-blind, placebo-controlled, parallel-group trial to assess the effect of 12-week treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide or dipeptidyl peptidase-4 inhibitor (DPP-4i) sitagliptin on the cardiovascular, renal and gastrointestinal system in insulin-naïve patients with type 2 diabetes (T2DM). - SAFEGUARD, Pleiotropic effects of incretin based therapies
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Both genders
- •-Age between 35 and 75 years. Females must be post-menopausal (no menses >1 year).
- •-Type 2 diabetes (HbA1c 6.5-9% DCCT or 48-75 mmol/mol IFCC), who are being treated with a stable dose of oral antihyperglycemic agents (either metformin alone, SU alone or a combination of metformin and SU) for at least 3 months prior to inclusion.
- •-BMI 25 - 40 kg/m2
- •- Caucasian;For the preceding pilot-study:
- •- Age between 18 and 50 years
- •- BMI 25 * 40 kg/m2
- •- Caucasian
排除标准
- •- GFR < 60 mL/min/1.73m2
- •- Current / chronic use of the following medication: thiazolidinediones, GLP-1RA, DPP-4i, glucocorticoids, NSAIDs, insulin, antimicrobial agents, chemotherapeutics or immune suppressants. Subjects on diuretics will only be excluded when these drugs (e.g. hydrochlorothiazide) cannot be stopped for the duration of the study.
- •- History of or actual pancreatic disease or impaired pancreatic exocrine function (defined as needed use of pancreatic enzymes)
- •- Active liver disease or a 3-fold elevation of liver enzymes (AST / ALT) at screening
- •- History of or actual malignancy (with the exception of basal cell carcinoma)
- •- Current urinary tract infection and active nephritis
- •-Recent (<6 months) history of cardiovascular disease, including acute coronary syndrome, stroke, transient ischemic neurologic disorder or chronic heart failure (New York Heart Association grade II-IV)
- •- Current atrial fibrillation
- •- Chronic infectious or auto-immune disease
- •- Substance and/or alcohol abuse, defined as >4 units alcohol/day (because of risk of pancreatitis)
- •- History of allergy/hypersensitivity to GLP-1RA, DPP-4i, inulin, para-aminohippuric acid, acetaminophen, secretin, MRI contrast agent or latex (component of PAH).
- •- Complaints compatible with or established gastroparesis and/or neurogenic bladder
- •- Any condition that has been recognized as a contra-indication for the use of GLP-1RA and DPP-4i, as listed in the respective SPCs
- •- History of or actual (severe) mental illness
- •- Inability to understand the study protocol and/or inability to give informed consent
- •- History of claustrophobia or presence of metal objects/implants (because of MRI protocol);For the preceding pilot-study:
- •Similar to the exclusion criteria for the main study, with the additions of:
- •- Subjects with a fasting plasma glucose *5.6 mmol/L, a 2-hour glucose of *7.8 mmol/L after a 75-grams oral glucose tolerance test, or a HbA1c of *6.5%
- •- Subjects using any kind of medication
研究者
相似试验
进行中（未招募）
不适用
The cardiovascular, renal and gastrointestinal effects of the gut-hormone based therapies liraglutide and sitagliptiMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2012-003256-36-NLVU University Medical Center
进行中（未招募）
不适用
Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants.Rotavirus gateroenteritisEUCTR2015-001545-81-Outside-EU/EEAGlaxoSmithKline Biologicals684
进行中（未招募）
1 期
A phase IV, randomised, double-blinded, placebo-controlled, parallel study to estimate the influence of vitamin D (D-CURE®) supplementation on the 25-hydroxyvitamin D serum concentration in patients aged over 50 years.Patients are over 50 years old and do not present any significant medical conditions.MedDRA version: 12.1Level: LLTClassification code 10047626Term: Vitamin D deficiencyEUCTR2010-023510-32-BEaboratoires SMB S.A.
进行中（未招募）
1 期
Dupilumab asthma sleep studyAsthmaEUCTR2020-001217-20-NLSanofi Aventis Recherche & Developpement578
进行中（未招募）
1 期
Dupilumab asthma sleep studyMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2020-001217-20-PTSanofi Aventis Recherche & Developpement578